9 results for author:"Harmange J.C." in Literature citations
Results Customize
› Repeat search in UniProtKB (1)
| Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors. Bode C.M., Boezio A.A., Albrecht B.K., Bellon S.F., Berry L., Broome M.A., Choquette D., Dussault I., Lewis R.T., Lin M.H. et al. Bioorg. Med. Chem. Lett. 22:4089-4093(2012) · Mapped (1) |
| Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors. Buchanan J.L., Newcomb J.R., Carney D.P., Chaffee S.C., Chai L., Cupples R., Epstein L.F., Gallant P., Gu Y., Harmange J.C. et al. Bioorg. Med. Chem. Lett. 21:2394-2399(2011) · UniProtKB (1) |
| Discovery of triazine-benzimidazoles as selective inhibitors of mTOR. Peterson E.A., Andrews P.S., Be X., Boezio A.A., Bush T.L., Cheng A.C., Coats J.R., Colletti A.E., Copeland K.W., DuPont M. et al. Bioorg. Med. Chem. Lett. 21:2064-2070(2011) · Mapped (1) |
| Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. Boezio A.A., Berry L., Albrecht B.K., Bauer D., Bellon S.F., Bode C., Chen A., Choquette D., Dussault I., Fang M. et al. Bioorg. Med. Chem. Lett. 19:6307-6312(2009) · Mapped (1) |
| Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. Albrecht B.K., Harmange J.C., Bauer D., Berry L., Bode C., Boezio A.A., Chen A., Choquette D., Dussault I., Fridrich C. et al. J. Med. Chem. 51:2879-2882(2008) · Mapped (1) |
| Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation. Harmange J.C., Weiss M.M., Germain J., Polverino A.J., Borg G., Bready J., Chen D., Choquette D., Coxon A., DeMelfi T. et al. J. Med. Chem. 51:1649-1667(2008) · Mapped (1) |
| Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors. Weiss M.M., Harmange J.C., Polverino A.J., Bauer D., Berry L., Berry V., Borg G., Bready J., Chen D., Choquette D. et al. J. Med. Chem. 51:1668-1680(2008) · Mapped (1) |
| Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis. La D.S., Belzile J., Bready J.V., Coxon A., DeMelfi T., Doerr N., Estrada J., Flynn J.C., Flynn S.R., Graceffa R.F. et al. J. Med. Chem. 51:1695-1705(2008) · Mapped (1) |
| Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. Potashman M.H., Bready J., Coxon A., DeMelfi T.M. Jr., DiPietro L., Doerr N., Elbaum D., Estrada J., Gallant P., Germain J. et al. J. Med. Chem. 50:4351-4373(2007) · Mapped (1) |